HOOKIPA Pharma Inc. (HOOK)

0.9302 +0.0123 (+1.34%) 收市：04:00PM EDT

HOOKIPA Pharma Inc.

350 Fifth Avenue
72nd Floor Suite 7240
New York, NY 10118
United States
431 890 6360
https://www.hookipapharma.com

版塊: Healthcare
行業: Biotechnology
全職員工: 151

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Joern Aldag	CEO & Director	848.34k	無	1959
Dr. Reinhard Kandera Ph.D.	CFO & Director	607.5k	無	1969
Prof. Rolf M. Zinkernagel M.D., Ph.D.	Co-Founder	無	無	1944
Mr. Andreas Bergthaler	Co-Founder	無	無	無
Mr. Lukas Flatz	Co-Founder	無	無	無
Dr. Roman Necina Ph.D.	Chief Operations Officer	無	無	1968
Dr. Klaus Orlinger Ph.D.	Chief Scientific Officer	無	無	1978
Mr. Matthew L. S. Beck	Executive Director of Investor Relations	無	無	無
Mr. Michael Szumera	Executive Director of Communications	無	無	無
Dr. Mark Winderlich Ph.D.	Chief Development Officer	無	無	1986

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-200 for the treatment of pembrolizumab which is in Phase 2 of clinical trial; HB-700, a preclinical development for treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers. Its lead product candidates are HB-400 for the treatment of Hepatitis B which is in Phase I of clinical trial and HB-500 for the treatment of HIV which is in Phase I of clinical trial. The company's preclinical stage products include HB-300 program for prostate cancer. It has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.

公司管治

截至 無 止，HOOKIPA Pharma Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。